Ultra-long-acting insulin degludec, an investigational compound from Novo Nordisk, has been featured in two studies in The Lancet showing a significant reduction in the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine. The two studies investigated both insulins in people with type 1 and type 2 diabetes.